Harris Rotman Biography and Net Worth

Senior Vice President, Regulatory Affairs of Centessa Pharmaceuticals

Dr. Harris Rotman joined Centessa in July 2022 as Senior Vice President, Regulatory Affairs. Harris has over 20 years of pharmaceutical industry experience with an additional 8 years of scientific research training. He has experience liaising with various regulatory agencies, and is proficient in investigational development, post-approval activities, application maintenance, advertising/promotion review, and medical writing. Harris has managed multiple worldwide developmental projects for regulatory in neuroscience, cardiovascular, renal, dermatologic, analgesic, addiction, aesthetic, and gastrointestinal therapeutic areas, including rare/orphan disease products. He has worked at Wyeth, Sanofi, Shire, Indivior, Endo, and SwanBio Therapeutics.

Harris received his BS in biological sciences from Rutgers University and his PhD in microbiology and molecular virology from Thomas Jefferson University. He then completed his postdoctoral fellowship at Hahnemann University Hospital

What is Harris Rotman's net worth?: The estimated net worth of Harris Rotman is at least $670,713.75 as of February 1st, 2024. Dr. Rotman owns 62,625 shares of Centessa Pharmaceuticals stock worth more than $670,714 as of April 9th. This net worth estimate does not reflect any other assets that Dr. Rotman may own. Learn More about Harris Rotman's net worth.
How do I contact Harris Rotman?: The corporate mailing address for Dr. Rotman and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at investorrelations@centessa.com. Learn More on Harris Rotman's contact information.
Has Harris Rotman been buying or selling shares of Centessa Pharmaceuticals?: Harris Rotman has not been actively trading shares of Centessa Pharmaceuticals during the past quarter. Most recently, Harris Rotman sold 4,267 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.10, for a transaction totalling $34,562.70. Following the completion of the sale, the senior vice president now directly owns 62,625 shares of the company's stock, valued at $507,262.50. Learn More on Harris Rotman's trading history.
Who are Centessa Pharmaceuticals' active insiders?: Centessa Pharmaceuticals' insider roster includes Karen Anderson (Chief People Officer), Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), David Grainger (Insider), Iqbal Hussain (General Counsel and Corporate Secretary), Aaron Kantoff (Director), Harris Rotman (Senior Vice President, Regulatory Affairs), Saurabh Saha (CEO), Gregory Weinhoff (Chief Business Officer), and Antoine Yver (EVP). Learn More on Centessa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Centessa Pharmaceuticals?: In the last year, insiders at the sold shares 34 times. They sold a total of 916,683 shares worth more than $15,287,044.28. The most recent insider tranaction occured on March, 25th when insider Gregory M Weinhoff sold 10,000 shares worth more than $163,400.00. Insiders at Centessa Pharmaceuticals own 11.6% of the company. Learn More about insider trades at Centessa Pharmaceuticals.
Information on this page was last updated on 3/25/2025.

Harris Rotman Insider Trading History at Centessa Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/1/2024	Sell	4,267	$8.10	$34,562.70	62,625
9/20/2023	Sell	37,484	$6.29	$235,774.36	33,500

Harris Rotman Buying and Selling Activity at Centessa Pharmaceuticals

Centessa Pharmaceuticals Company Overview

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Today's Range

Now: $10.71

$10.51

$12.39

50 Day Range

MA: $15.83

$10.71

$19.03

2 Week Range

Now: $10.71

$7.75

$19.09

Volume

1,234,487 shs

Average Volume

574,379 shs

Market Capitalization

$1.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53